Checkpoint inhibitors, which target proteins like PD-1/PD-L1 and CTLA-4 to release “brakes” on immune cells, have shown remarkable success in many cancers, but often encounter resistance within gliomas [89,90]. This evidence concerns the gene CD274 and central nervous system cancer.